SUSAN PALMER: Open Payments
NPI 1497396923 · GRAND ISLAND, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$578 in 49 payments from 8 companies in 2025. Trend: 2023 $683 · 2024 $510 · 2025 $578
Food & beverage: $578
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $264 |
| Otsuka America Pharmaceutical, Inc. | 13 | $181 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Janssen Pharmaceuticals, Inc | 1 | $14 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: VRAYLAR, ABILIFY MAINTENA, REXULTI, FANAPT, TRINTELLIX, CAPLYTA, Qelbree, SPRAVATO.
Industry payments across NE — which companies pay providers there.
